Ellen Townley

National Institute of Allergy and Infectious Diseases

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study”.

Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The Lancet HIV(2024)10.1016/s2352-3018(23)00300-4

N/A

1.1DataRank · unranked

29 citations

Edmund V. Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A. Marzinke, Cynthia McCoig +36 more

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

Clinical Infectious Diseases(2021)10.1093/cid/ciab665

N/A

0.972DataRank · unranked

34 citations

Rada Savic, Paula Britto, Priya Jayachandran, Lubbe Wiesner, Grace Montepiedra +15 more

Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study

The Lancet HIV(2024)10.1016/s2352-3018(23)00301-6

N/A

0.959DataRank · unranked

26 citations

Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman +32 more

Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation study

The Lancet HIV(2023)10.1016/s2352-3018(23)00107-8

N/A

0.675DataRank · unranked

13 citations

Jennifer J. Kiser, Lauren Ziemba, S. M. Ward, Yasha Rani, Tim R. Cressey +24 more

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The Lancet HIV(2025)10.1016/s2352-3018(24)00344-8

N/A

0.535DataRank · unranked

12 citations

Kristin Baltrusaitis, Brookie M. Best, Jack Moye, Ellen Townley, Avy Violari +36 more

Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014

Journal of the Pediatric Infectious Diseases Society(2023)10.1093/jpids/piad078

N/A

0.208DataRank · unranked

3 citations

Linda Aurpibul, Brookie M. Best, Xiang Li, Meredith G. Warshaw, Hong Wan +54 more

The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial

UNC Libraries(2020)10.17615/rem0-jq49

N/A

0DataRank · unranked

0 citations

Amanda Selin, P. Andrew, Oliver Laeyendecker, Immitrude Mokoena, F. Xavier Gómez‐Olivé +14 more

Participant acceptability and clinician satisfaction of cognitive behavioural therapy and medication management algorithm compared with enhanced standard care for treatment of depression among youth with HIV

Journal of Child and Adolescent Mental Health(2024)10.2989/17280583.2024.2387632

N/A

0DataRank · unranked

2 citations

Kristin Baltrusaitis, Betsy D. Kennard, Graham J. Emslie, Chelsea Krotje, Kevin Knowles +9 more

Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014

JAIDS Journal of Acquired Immune Deficiency Syndromes(2022)10.1097/qai.0000000000003116

N/A

0DataRank · unranked

3 citations

Ka Lai Yee, Kathryn P. Gray, Mounika Yedla, Hong Wan, Nicole H. Tobin +17 more